CompanyCLLSNasdaqParis, Lle-De-France

Cellectis S.A.

Cellectis develops genome engineering platforms including gene editing, base editing, epigenetic editing, and transcriptional regulation for genetic medicines.

Stories only

SEC EDGAR ClinicalTrials.gov cellectis.com

6-KSep 14Latest SEC filing, period to Sep 14

Aug 6Latest story

August 2026

Cellectis reports Q2 2026 results as lasme-cel gains FDA RMAT status

Aug 6Quarterly updateCellectis S.A.